Follow the Alembic Pharma stock price and the full directors' dealings record of the company, a listed equity based in India. Shares are quoted on IN IN, under the supervision of SEBI (PIT + SAST). Market capitalisation: €151bn. The latest transaction was filed on 19 June 2026 (Acquisition). Among the most active insiders: Nirayu Private Limited. Every trade is openly available.
6
Insider Decl.
n/a
Thresholds
€2m
6 ops.
Buy Volume
n/a
n/a
Sell Volume
32Σ signal
Buys €2mn/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 9,673 of 27,969 companies
59.2
score / 100
Value
47
Quality
71
FCF yld1.8%
Earn yld4.2%
EV/EBITDA15.7x
ROE12%
Gross mgn67%
Net mgn9.4%
Debt/EBITDA1.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
60,000 shares@ ₹758.0038.1% of flowEquity SharesMarket PurchaseSEBI:3660fa3496803de67527703cc3e8ff54a498d345
Canonical exit: 23 Aug 2026 (T+90)
6 of 6 declarations
About Alembic Pharma
Alembic Pharma is an Indian pharmaceutical company that focuses on the research, development, and manufacturing of generic drugs and pharmaceutical products. It is listed on the Bombay Stock Exchange under the symbol XBOM.